The European pharmaceutical industry is entering a new era. With the implementation of the European Union Health Technology Assessment (EU HTA) Regulation, companies must rethink how they generate clinical evidence, align cross-functional teams, and prepare for successful market access across Europe.
The introduction of the European Union Health Technology Assessment (EU HTA) Regulation marks one of the most significant changes to pharmaceutical market access in decades.
For life science companies, regulatory approval alone is no longer enough.
Success now depends on generating clinical evidence that satisfies regulators, HTA bodies, healthcare payers, and reimbursement authorities simultaneously.
Organisations that continue treating Regulatory Affairs, Clinical Development, HEOR, Market Access, Pricing & Reimbursement, and Real-World Evidence (RWE) as separate functions risk delays, increased development costs, reimbursement challenges, and slower patient access.
The future belongs to companies that embrace early evidence planning and build an integrated strategy from the earliest stages of product development.
Why Early Alignment Is Becoming the New Competitive Advantage
Historically, pharmaceutical companies focused primarily on achieving regulatory approval from the European Medicines Agency (EMA).
Today, the commercial success of an innovative medicine depends on much more.
Healthcare systems across Europe increasingly expect strong evidence demonstrating:
- Comparative clinical effectiveness
- Patient-centred outcomes
- Appropriate PICO strategy
- Long-term clinical benefit
- Real-World Evidence (RWE)
- Economic value
- Appropriate comparator selection
- Healthcare system impact
Waiting until regulatory approval to think about reimbursement is no longer a viable strategy.
Companies that begin integrating Regulatory, HTA and Market Access planning during Phase II and Phase III development are better positioned to accelerate patient access while reducing costly evidence gaps later in the product lifecycle.
Why This Matters for Pharmaceutical and Life Science Organisations
The EU HTA Regulation affects far more than regulatory teams.
It requires cross-functional collaboration across almost every strategic department involved in product development and commercialisation.
Pharmaceutical Companies
Global and regional pharmaceutical companies developing innovative therapies must ensure their evidence packages satisfy both regulatory agencies and HTA organisations.
Biotechnology Companies
Biotech organisations often operate with limited internal HTA capabilities, making early strategic planning critical for successful reimbursement across Europe.
Medical Device & MedTech Companies
Manufacturers launching innovative medical technologies increasingly require robust clinical and economic evidence to support reimbursement decisions.
Digital Health & Software as a Medical Device (SaMD)
AI-powered diagnostics, digital therapeutics and remote monitoring solutions require comprehensive evidence generation to demonstrate clinical and economic value.
Diagnostics & Precision Medicine
Companion diagnostics and genomic testing solutions must increasingly demonstrate value beyond analytical performance by proving real-world clinical utility.
Contract Research Organisations (CROs)
Clinical research organisations are expanding beyond trial execution by supporting sponsors with integrated evidence generation, RWE and HTA readiness.
Healthcare Consulting Organisations
Specialist consultancies play an increasingly important role in helping companies navigate complex European regulatory and reimbursement pathways.
The Rise of Integrated Evidence Planning (IEP)
One of the strongest trends across the pharmaceutical industry is the adoption of Integrated Evidence Planning (IEP).
Rather than generating evidence independently across different departments, organisations are building unified evidence strategies that connect:
- Regulatory Affairs
- Clinical Development
- Medical Affairs
- HEOR
- Real-World Evidence
- Market Access
- Pricing & Reimbursement
- Commercial Strategy
This integrated approach enables organisations to answer regulatory and payer questions before they become barriers to market access.
The Growing Importance of Real-World Evidence (RWE)
Real-World Evidence is no longer viewed as simply a post-launch requirement.
It has become an essential component of modern evidence generation.
Companies increasingly use RWE to:
- Support HTA submissions
- Demonstrate long-term effectiveness
- Validate clinical trial outcomes
- Address evidence gaps
- Strengthen reimbursement negotiations
- Support value-based healthcare
- Inform payer decision making
When integrated early into development programmes, RWE becomes a powerful asset that complements traditional clinical trial evidence.
How DLRC Group Helps Life Science Organisations Navigate EU HTA
As regulatory requirements continue to evolve, organisations increasingly require specialist expertise capable of integrating scientific, regulatory and commercial strategy.
DLRC Group is an award-winning consultancy comprising more than 80 highly qualified and experienced professionals operating from offices across the United Kingdom, Germany and the United States.
With extensive expertise spanning Regulatory Affairs, HTA, Market Access, Clinical Development and evidence generation, DLRC supports pharmaceutical, biotechnology, medical device and healthcare innovators throughout the entire product lifecycle.
From early development through post-licensing activities, DLRC develops and executes phase-appropriate strategies that connect:
- Regulatory planning
- Clinical evidence generation
- Health Technology Assessment
- Market Access strategy
- Pricing & Reimbursement planning
- Scientific consultation strategy
- Evidence gap assessment
- Commercial readiness
Their multidisciplinary experts bring experience from pharmaceutical companies, medical device manufacturers and regulatory agencies, enabling clients to successfully navigate one of the world’s most complex healthcare environments.
DLRC Group is also a Certified B Corporation (B Corp), reflecting its commitment to high standards of governance, customer value, environmental responsibility and community impact.
How DLRC's Solutions Support Successful European Product Launches
DLRC provides strategic consulting across several critical areas that directly influence commercial success under the EU HTA framework.
Regulatory-Aligned HTA Strategy
Helping organisations align regulatory planning with future reimbursement requirements from the earliest stages of development.
EU HTA Readiness
Preparing companies for Joint Clinical Assessment (JCA) by identifying evidence requirements before submission.
Market Access Strategy
Supporting market access planning across European healthcare systems through integrated payer-focused strategies.
Evidence Gap Assessment
Identifying potential weaknesses within clinical evidence programmes before they impact regulatory approval or reimbursement.
Scientific Consultation Strategy
Helping organisations engage with regulators and HTA stakeholders early to optimise evidence generation programmes.
Pricing & Reimbursement Planning
Supporting commercial teams with strategies that improve reimbursement success and accelerate patient access.
Real-World Evidence Strategy
Designing evidence-generation programmes that strengthen payer confidence and demonstrate long-term product value.
One of the highlights of this year’s programme will be a presentation by Carolin Knorr, HTA & Market Access Principal Consultant at DLRC Group.
With over 20 years of experience at the intersection of HTA, Pricing & Reimbursement and Regulatory Affairs, Carolin has helped healthcare developers successfully connect regulatory strategy with European market access planning.
Her expertise includes:
- EU HTA readiness
- Scientific consultation strategy
- HTA planning
- Evidence gap assessment
- Pricing & reimbursement considerations
- Integrated Market Access strategy
- Regulatory alignment
Featured Summit Session
EU HTA Rewards Early Alignment on Clinical Evidence Requirements
Integrating Regulatory, HTA and Market Access Strategy in Europe
During this session, Carolin will explore how organisations can successfully align evidence generation with evolving European HTA expectations while improving regulatory and commercial outcomes.
Whether you are preparing for upcoming EU HTA requirements or looking to strengthen your integrated evidence strategy, this session will provide practical insights that can immediately support your development programmes.
If your organisation is involved in:
- Market Access
- HEOR
- Real-World Evidence
- Regulatory Affairs
- Clinical Development
- Pricing & Reimbursement
- Medical Affairs
- Evidence Generation
- EU HTA Strategy
- Commercial Excellence
this is an event you should not miss.
📅 21–22 October 2026
📍 Inntel Hotels Amsterdam Landmark, Amsterdam, Netherlands
The European RWE & Market Access Summit brings together leading pharmaceutical companies, biotechnology innovators, medical device manufacturers, regulators, HTA experts, payers, academic leaders and solution providers to discuss the future of evidence generation, reimbursement and patient access across Europe.
If you are currently preparing for:
- EU HTA implementation
- Joint Clinical Assessment (JCA)
- Integrated Evidence Planning
- Regulatory strategy
- Market Access planning
- Scientific consultation
- Evidence gap analysis
- Pricing & Reimbursement strategy
- Real-World Evidence generation
we encourage you to meet Carolin Knorr during the summit.
This is an excellent opportunity to discuss your organisation’s challenges, explore practical solutions and learn how DLRC Group’s multidisciplinary expertise can support successful product development and European market access.
Final Thoughts
The future of European healthcare innovation depends on more than scientific excellence.
Success now requires organisations to think beyond regulatory approval by integrating clinical development, Regulatory Affairs, HTA, Market Access, Pricing & Reimbursement and Real-World Evidence into one unified evidence strategy.
Companies that embrace early alignment will not only reduce development risk but also accelerate patient access, improve reimbursement success and strengthen commercial outcomes across Europe.
As the EU HTA Regulation continues to reshape the life sciences landscape, partnering with experienced experts such as DLRC Group can help organisations confidently navigate these changes and transform evidence into successful market access.
We look forward to welcoming Carolin Knorr and the DLRC Group team to the European RWE & Market Access Summit 2026, where they will share practical insights into building integrated evidence strategies for the next generation of healthcare innovation.
About the European RWE & Market Access Summit
The European RWE & Market Access Summit 2026 is Europe’s premier meeting point for pharmaceutical, biotechnology and healthcare leaders focused on Real-World Evidence, EU HTA, Pricing & Reimbursement, HEOR, Regulatory Affairs, Evidence Generation and Market Access. Bringing together senior decision-makers, the summit provides a platform to exchange best practices, explore innovative solutions and build partnerships that accelerate patient access across Europe.